Leishmaniasis is a tropical infectious disease caused by the protozoan Leishmania parasite.
The disease is transmitted by female sand flies and, depending on the infecting parasite …

New drugs are needed to control leishmaniasis and efforts are currently on-going to counter
the neglect of this disease. We discuss here the utility and the impact of associating drug …

Leishmaniasis is a serious medical issue in many countries around the World, but it remains
largely neglected in terms of research investment for developing new control and treatment …

Leishmaniasis is a neglected parasitic disease for which the current antileishmania
therapeutics are hampered by drug toxicity, high cost, need for parenteral administration …

For decades antimonials were the drugs of choice for the treatment of visceral leishmaniasis
(VL), but the recent emergence of resistance has made them redundant as first-line therapy …

Two major leishmaniasis treatments have shown a significant decrease in effectiveness in
the last few decades, mostly in the Indian subcontinent but also in other endemic areas …

Leishmania donovani is the causative agent of the potentially fatal disease visceral
leishmaniasis (VL). Chemotherapeutic options available to treat VL are limited and often …

The ability of Leishmania to survive in their insect or mammalian host is dependent upon an
ability to sense and adapt to changes in the microenvironment. However, little is known …

Leishmania donovani is an intracellular protozoan parasite that causes leishmaniasis, which
can range from a self-healing cutaneous disease to a fatal visceral disease depending on …

The first-line treatment for Leishmania donovani-induced cutaneous leishmaniasis (CL) in
Sri Lanka is intra-lesional sodium stibogluconate (IL-SSG). Antimony failures in …